38 mins. ago
Nasdaq (NASDAQ: $NDAQ) has invested $100 million U.S. in Payward, the parent company of cryptocurrency exchange Kraken.
The investment by Nasdaq was part of a new funding round that valued Payward at $21 billion U.S. The company had been seeking new capital at a $20 billion U.S. valuation.
Nasdaq's investment also comes as the exchange known for listing technology stocks develops tokenized market infrastructure and prepares for around the clock trading.
More From Cryptoprowl:
MEXC Launches Earn Plus With Limited-Time Event Offering Up to 800% APR Booster
#company #NDAQ #kraken
The investment by Nasdaq was part of a new funding round that valued Payward at $21 billion U.S. The company had been seeking new capital at a $20 billion U.S. valuation.
Nasdaq's investment also comes as the exchange known for listing technology stocks develops tokenized market infrastructure and prepares for around the clock trading.
More From Cryptoprowl:
MEXC Launches Earn Plus With Limited-Time Event Offering Up to 800% APR Booster
#company #NDAQ #kraken
1 day ago
Nasdaq (Nasdaq: NDAQ) announced on Sep. 10 that its strategic investment arm, Nasdaq Ventures, is investing $100 million in Payward, the parent company of the Kraken crypto exchange.
The two companies also announced a partnership to launch the Equity Token (NET) framework by the second quarter of 2027.
"The next era of market evolution will be defined by how efficiently and seamlessly capital and ****** ets move across the financial system with durable liquidity," said Nasdaq President Tal Cohen. "Expanding our relationship with Payward reflects our conviction that the company can play an important role in building the infrastructure that supports this evolution."
Related: What are tokenized stocks? Explained
Nasdaq and Payward had announced the NET partnership in March to support the tokenization of equities within "existing regulatory frameworks" which gives public issuers more control over the tokenized versions of their companies' stocks.
#NASDAQ #Companies
The two companies also announced a partnership to launch the Equity Token (NET) framework by the second quarter of 2027.
"The next era of market evolution will be defined by how efficiently and seamlessly capital and ****** ets move across the financial system with durable liquidity," said Nasdaq President Tal Cohen. "Expanding our relationship with Payward reflects our conviction that the company can play an important role in building the infrastructure that supports this evolution."
Related: What are tokenized stocks? Explained
Nasdaq and Payward had announced the NET partnership in March to support the tokenization of equities within "existing regulatory frameworks" which gives public issuers more control over the tokenized versions of their companies' stocks.
#NASDAQ #Companies
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
14 days ago
Pfizer Inc. (NYSE:PFE) and Abbott Laboratories (NYSE:ABT) offer investors two very different dividend stories. Pfizer (NYSE:PFE) is working to rebuild growth before major patent expirations arrive, while Abbott (NYSE:ABT) is combining a long dividend-growth record with a more diversified healthcare portfolio. Pfizer (NYSE:PFE) may offer turnaround potential, but Abbott's (NYSE:ABT) latest results present the steadier investment case.
Pfizer's (NYSE:PFE) non-COVID portfolio is beginning to carry more of the business. Revenue excluding Comirnaty and Paxlovid grew 5% operationally in fiscal Q2 2026, while launched and acquired products generated $3.2 billion and increased 18% operationally. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in first-line locally advanced or metastatic urothelial cancer and uptake in muscle-invasive bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. This broader contribution is encouraging because Pfizer needs several products to offset declining COVID revenue and future patent losses.
Stronger non-COVID performance allowed Pfizer (NYSE:PFE) to raise the midpoint of its 2026 revenue guidance by $500 million, despite reducing its COVID-product forecast from approximately $5 billion to $4 billion. Its cost programs should provide further support, as management expects combined savings of approximately $9.7 billion through 2029 across its cost-realignment and manufacturing-optimization initiatives.
Abbott's (NYSE:ABT) advantage is the breadth of its growth. Second-quarter sales increased 13% on a reported basis and 4.8% on a comparable basis, while adjusted EPS rose 4% to $1.31. Medical Devices remained Abbott's (NYSE:ABT) largest segment and an important growth contributor, with sales rising 8.4% on a comparable basis. Growth was led by electrophysiology, rhythm management, heart failure, and diabetes care, with continuous-glucose-monitor sales increasing 9.5% comparably.
The Exact Sciences acquisition also expanded Abbott's (NYSE:ABT) diagnostics business. Diagnostics revenue reached $3.09 billion, rising 42.3% reported and 2.9% comparably. Within the segment, Cancer Diagnostics delivered 13.3% comparable growth as Cologuard benefited from increasing numbers of new and repeat users.
#Growth #billion #covid #revenue
Pfizer's (NYSE:PFE) non-COVID portfolio is beginning to carry more of the business. Revenue excluding Comirnaty and Paxlovid grew 5% operationally in fiscal Q2 2026, while launched and acquired products generated $3.2 billion and increased 18% operationally. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in first-line locally advanced or metastatic urothelial cancer and uptake in muscle-invasive bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. This broader contribution is encouraging because Pfizer needs several products to offset declining COVID revenue and future patent losses.
Stronger non-COVID performance allowed Pfizer (NYSE:PFE) to raise the midpoint of its 2026 revenue guidance by $500 million, despite reducing its COVID-product forecast from approximately $5 billion to $4 billion. Its cost programs should provide further support, as management expects combined savings of approximately $9.7 billion through 2029 across its cost-realignment and manufacturing-optimization initiatives.
Abbott's (NYSE:ABT) advantage is the breadth of its growth. Second-quarter sales increased 13% on a reported basis and 4.8% on a comparable basis, while adjusted EPS rose 4% to $1.31. Medical Devices remained Abbott's (NYSE:ABT) largest segment and an important growth contributor, with sales rising 8.4% on a comparable basis. Growth was led by electrophysiology, rhythm management, heart failure, and diabetes care, with continuous-glucose-monitor sales increasing 9.5% comparably.
The Exact Sciences acquisition also expanded Abbott's (NYSE:ABT) diagnostics business. Diagnostics revenue reached $3.09 billion, rising 42.3% reported and 2.9% comparably. Within the segment, Cancer Diagnostics delivered 13.3% comparable growth as Cologuard benefited from increasing numbers of new and repeat users.
#Growth #billion #covid #revenue
17 days ago
Guinness Global Innovators, an investment management company, recently released its Q2 2026 quarterly investor update for its "Guinness Global Innovators Fund". You can download the letter here. The Guinness Global Innovators Fund focuses on investing in global companies that benefit from innovation in technology, communication, globalization, and management strategies. In the second quarter of 2026, the Guinness Global Innovators Fund returned 13.8% in GBP, compared with 13.0% for the MSCI World Index and 13.1% for the IA Global sector average. Easing Middle East tensions, falling oil prices, and renewed enthusiasm for artificial intelligence helped reverse much of the caution seen earlier in the year, with investors rotating back toward growth stocks and AI infrastructure beneficiaries. The Fund benefited from its overweight position in the Information Technology sector, while its overweight position in Communication Services detracted. Avoiding weaker Utilities, Materials, and Energy also supported relative performance. Also, please check the Fund's top five holdings to see its best picks for 2026.
In its second-quarter 2026 investor letter, Guinness Global Innovators Fund highlighted Nasdaq, Inc. (NASDAQ:NDAQ) as a new holding. Nasdaq, Inc. (NASDAQ:NDAQ) operates as a technology company that serves capital markets and other industries. On August 21, 2026, Nasdaq, Inc. (NASDAQ:NDAQ) closed at $98.22 per share. One-month return of Nasdaq, Inc. (NASDAQ:NDAQ) was 4.56% and its shares gained 4.13% over the past 52 weeks. Nasdaq, Inc. (NASDAQ:NDAQ) has a market capitalization of $54.9 billion.
Guinness Global Innovators Fund stated the following regarding Nasdaq, Inc. (NASDAQ:NDAQ) in its Q2 2026 investor letter:
"Nasdaq, Inc. (NASDAQ:NDAQ) is best understood not as a traditional exchange but as a global technology, data, and ******* ytics company that happens to own a major stock exchange, a positioning it has deliberately built since its 2017 strategic pivot away from transaction-driven revenue towards higher-growth, higher-margin software and ******* ytics. Nasdaq's business is diversified across three segments. Through its Financial Technology segment, the firm is strategically positioned to benefit from a structural rise in compliance and transparency requirements as regulators demand more granular and frequent reporting from banks globally. This segment also houses Calypso, a trading and risk-management platform whose demand is underpinned by the growing complexity of trading, collateral, and risk requirements at large financial institutions. The Capital Access Platforms segment includes listing fees, market data subscriptions and index licensing on products such as the Nasdaq-100. Lastly, its exchange business, although originally the direct driver of the business, has become more of an enabler for other business segments, as trading activity generates proprietary pricing data that the company repackages and monetises, while providing the
In its second-quarter 2026 investor letter, Guinness Global Innovators Fund highlighted Nasdaq, Inc. (NASDAQ:NDAQ) as a new holding. Nasdaq, Inc. (NASDAQ:NDAQ) operates as a technology company that serves capital markets and other industries. On August 21, 2026, Nasdaq, Inc. (NASDAQ:NDAQ) closed at $98.22 per share. One-month return of Nasdaq, Inc. (NASDAQ:NDAQ) was 4.56% and its shares gained 4.13% over the past 52 weeks. Nasdaq, Inc. (NASDAQ:NDAQ) has a market capitalization of $54.9 billion.
Guinness Global Innovators Fund stated the following regarding Nasdaq, Inc. (NASDAQ:NDAQ) in its Q2 2026 investor letter:
"Nasdaq, Inc. (NASDAQ:NDAQ) is best understood not as a traditional exchange but as a global technology, data, and ******* ytics company that happens to own a major stock exchange, a positioning it has deliberately built since its 2017 strategic pivot away from transaction-driven revenue towards higher-growth, higher-margin software and ******* ytics. Nasdaq's business is diversified across three segments. Through its Financial Technology segment, the firm is strategically positioned to benefit from a structural rise in compliance and transparency requirements as regulators demand more granular and frequent reporting from banks globally. This segment also houses Calypso, a trading and risk-management platform whose demand is underpinned by the growing complexity of trading, collateral, and risk requirements at large financial institutions. The Capital Access Platforms segment includes listing fees, market data subscriptions and index licensing on products such as the Nasdaq-100. Lastly, its exchange business, although originally the direct driver of the business, has become more of an enabler for other business segments, as trading activity generates proprietary pricing data that the company repackages and monetises, while providing the
18 days ago
The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday's blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer's (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in one therapeutic area. For investors, this is ultimately a choice between an unfinished turnaround and a stronger growth story still searching for greater breadth.
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.
#NYSE #million #gild
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.
#NYSE #million #gild
18 days ago
Guinness Global Innovators, an investment management company, recently released its Q2 2026 quarterly investor update for its "Guinness Global Innovators Fund". You can download the letter here. The Guinness Global Innovators Fund focuses on investing in global companies that benefit from innovation in technology, communication, globalization, and management strategies. In the second quarter of 2026, the Guinness Global Innovators Fund returned 13.8% in GBP, compared with 13.0% for the MSCI World Index and 13.1% for the IA Global sector average. Easing Middle East tensions, falling oil prices, and renewed enthusiasm for artificial intelligence helped reverse much of the caution seen earlier in the year, with investors rotating back toward growth stocks and AI infrastructure beneficiaries. The Fund benefited from its overweight position in the Information Technology sector, while its overweight position in Communication Services detracted. Avoiding weaker Utilities, Materials, and Energy also supported relative performance. Also, please check the Fund's top five holdings to see its best picks for 2026.
In its second-quarter 2026 investor letter, Guinness Global Innovators Fund highlighted Nasdaq, Inc. (NASDAQ:NDAQ) as a new holding. Nasdaq, Inc. (NASDAQ:NDAQ) operates as a technology company that serves capital markets and other industries. On August 21, 2026, Nasdaq, Inc. (NASDAQ:NDAQ) closed at $98.22 per share. One-month return of Nasdaq, Inc. (NASDAQ:NDAQ) was 4.56% and its shares gained 4.13% over the past 52 weeks. Nasdaq, Inc. (NASDAQ:NDAQ) has a market capitalization of $54.9 billion.
Guinness Global Innovators Fund stated the following regarding Nasdaq, Inc. (NASDAQ:NDAQ) in its Q2 2026 investor letter:
"Nasdaq, Inc. (NASDAQ:NDAQ) is best understood not as a traditional exchange but as a global technology, data, and ****** ytics company that happens to own a major stock exchange, a positioning it has deliberately built since its 2017 strategic pivot away from transaction-driven revenue towards higher-growth, higher-margin software and ****** ytics. Nasdaq's business is diversified across three segments. Through its Financial Technology segment, the firm is strategically positioned to benefit from a structural rise in compliance and transparency requirements as regulators demand more granular and frequent reporting from banks globally. This segment also houses Calypso, a trading and risk-management platform whose demand is underpinned by the growing complexity of trading, collateral, and risk requirements at large financial institutions. The Capital Access Platforms segment includes listing fees, market data subscriptions and index licensing on products such as the Nasdaq-100. Lastly, its exchange business, although originally the direct driver of the business, has become more of an enabler for other business segments, as trading activity generates proprietary pricing data that the company repackages and monetises, while providing the f
In its second-quarter 2026 investor letter, Guinness Global Innovators Fund highlighted Nasdaq, Inc. (NASDAQ:NDAQ) as a new holding. Nasdaq, Inc. (NASDAQ:NDAQ) operates as a technology company that serves capital markets and other industries. On August 21, 2026, Nasdaq, Inc. (NASDAQ:NDAQ) closed at $98.22 per share. One-month return of Nasdaq, Inc. (NASDAQ:NDAQ) was 4.56% and its shares gained 4.13% over the past 52 weeks. Nasdaq, Inc. (NASDAQ:NDAQ) has a market capitalization of $54.9 billion.
Guinness Global Innovators Fund stated the following regarding Nasdaq, Inc. (NASDAQ:NDAQ) in its Q2 2026 investor letter:
"Nasdaq, Inc. (NASDAQ:NDAQ) is best understood not as a traditional exchange but as a global technology, data, and ****** ytics company that happens to own a major stock exchange, a positioning it has deliberately built since its 2017 strategic pivot away from transaction-driven revenue towards higher-growth, higher-margin software and ****** ytics. Nasdaq's business is diversified across three segments. Through its Financial Technology segment, the firm is strategically positioned to benefit from a structural rise in compliance and transparency requirements as regulators demand more granular and frequent reporting from banks globally. This segment also houses Calypso, a trading and risk-management platform whose demand is underpinned by the growing complexity of trading, collateral, and risk requirements at large financial institutions. The Capital Access Platforms segment includes listing fees, market data subscriptions and index licensing on products such as the Nasdaq-100. Lastly, its exchange business, although originally the direct driver of the business, has become more of an enabler for other business segments, as trading activity generates proprietary pricing data that the company repackages and monetises, while providing the f
1 month ago
New York-based Nasdaq, Inc. (NDAQ) operates as a technology company that serves capital markets and other industries in the United States and internationally. The company has a market cap of $52.9 billion and operates through three segments: Capital Access Platforms, Financial Technology, and Market Services, and distributes historical and real-time market data, develops and licenses Nasdaq-branded indices and financial products, and more.
NDAQ stock has lagged behind the broader market over the past year, declining 1.9% compared to the S&P 500 Index's ($SPX) 22.4% surge. Moreover, in 2026, the stock has fallen by nearly 2.6%, underperforming the SPX's 13.3% rise.
Don't ****** ume Micron Will Share SanDisk's Fate. Here's Why.
The Nvidia-SpaceX Deal Is Sending a Clear Signal on AI Dominance
A $72 Billion Reason to Buy Caterpillar Stock Now
#market #technology #financial #operates
NDAQ stock has lagged behind the broader market over the past year, declining 1.9% compared to the S&P 500 Index's ($SPX) 22.4% surge. Moreover, in 2026, the stock has fallen by nearly 2.6%, underperforming the SPX's 13.3% rise.
Don't ****** ume Micron Will Share SanDisk's Fate. Here's Why.
The Nvidia-SpaceX Deal Is Sending a Clear Signal on AI Dominance
A $72 Billion Reason to Buy Caterpillar Stock Now
#market #technology #financial #operates
2 months ago
American Bitcoin (NASDAQ: $ABTC) has conducted a controversial reverse stock split to avoid being delisted from the Nasdaq (NASDAQ: $NDAQ) exchange on which its shares trade.
American Bitcoin is the Bitcoin (CRYPTO: $BTC) mining company co-founded by U.S. President Donald Trump's son Eric and majority-owned by Canada's Hut 8 (NASDAQ: $HUT).
The company's shares are currently trading at $0.56 U.S. per share, having fallen 91% since going public last year.
More From Cryptoprowl:
Ripple, The Company Behind XRP, Is Valued At $50 Billion
American Bitcoin is the Bitcoin (CRYPTO: $BTC) mining company co-founded by U.S. President Donald Trump's son Eric and majority-owned by Canada's Hut 8 (NASDAQ: $HUT).
The company's shares are currently trading at $0.56 U.S. per share, having fallen 91% since going public last year.
More From Cryptoprowl:
Ripple, The Company Behind XRP, Is Valued At $50 Billion
3 months ago
Eli Lilly (NYSE: LLY) is basically hitting it out of the park right now. Sales of its industry-leading GLP-1 weight-loss drugs Mounjaro and Zepbound rose 125% and 80%, respectively, in the first quarter of 2026, driving a huge 56% sales gain for the drug giant. There's a reason why the stock is up more than 400% over the past five years.
There's just one small problem for dividend investors: Eli Lilly's dividend yield is a tiny 0.6%. That's well below the S&P 500 index's (SNPINDEX: ^GSPC) roughly 1% yield and the average drug stock's 1.6%. Eli Lilly competitor Pfizer (NYSE: PFE) has a 6.6% yield, which is more than 10x higher! Is it the better dividend stock?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
While Eli Lilly is hitting on all cylinders today, Pfizer is not. That's why the pharmaceutical giant's stock is down 30% over the past five years and nearly 60% from the high it reached in late 2021. There are a couple of problems worth noting.
First, Pfizer was one of the companies that quickly created a COVID vaccine during the coronavirus pandemic. Sales of COVID vaccines haven't lived up to expectations now that the world has basically learned to live with the illness. In addition, Pfizer has a number of highly profitable drugs set to lose patent protection over the next couple of years. Oncology drug Ibrance will lose patent protection in 2027, with cardiovascular drugs Eliquis and Vyndaqel getting hit the following year.
There's just one small problem for dividend investors: Eli Lilly's dividend yield is a tiny 0.6%. That's well below the S&P 500 index's (SNPINDEX: ^GSPC) roughly 1% yield and the average drug stock's 1.6%. Eli Lilly competitor Pfizer (NYSE: PFE) has a 6.6% yield, which is more than 10x higher! Is it the better dividend stock?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
While Eli Lilly is hitting on all cylinders today, Pfizer is not. That's why the pharmaceutical giant's stock is down 30% over the past five years and nearly 60% from the high it reached in late 2021. There are a couple of problems worth noting.
First, Pfizer was one of the companies that quickly created a COVID vaccine during the coronavirus pandemic. Sales of COVID vaccines haven't lived up to expectations now that the world has basically learned to live with the illness. In addition, Pfizer has a number of highly profitable drugs set to lose patent protection over the next couple of years. Oncology drug Ibrance will lose patent protection in 2027, with cardiovascular drugs Eliquis and Vyndaqel getting hit the following year.
1 yr. ago
$NBBI Posted News
https://cutt.ly/5rnlBRbd
#IHub_StockPosts #NDAQ #NASDAQ #AI #wsj #nytimes #business #reuters #forbes #jakepaul #cnn #bet #FoxNews #latimes #Crainschicago #usatoday #barronsonline #IBDinvestors #yahoofinance #espn #WGN #Apple #Tsla #IR
https://cutt.ly/5rnlBRbd{#... $NBBI Posted News
https://cutt.ly/5rnlBRbd
#IHub_StockPosts #NDAQ #NASDAQ #AI #wsj #nytimes #business #reuters #forbes #jakepaul #cnn #bet #FoxNews #latimes #Crainschicago #usatoday #barronsonline #IBDinvestors #yahoofinance #espn #WGN #Apple #Tsla #IR
https://cutt.ly/5rnlBRbd
https://cutt.ly/5rnlBRbd
#IHub_StockPosts #NDAQ #NASDAQ #AI #wsj #nytimes #business #reuters #forbes #jakepaul #cnn #bet #FoxNews #latimes #Crainschicago #usatoday #barronsonline #IBDinvestors #yahoofinance #espn #WGN #Apple #Tsla #IR
https://cutt.ly/5rnlBRbd{#... $NBBI Posted News
https://cutt.ly/5rnlBRbd
#IHub_StockPosts #NDAQ #NASDAQ #AI #wsj #nytimes #business #reuters #forbes #jakepaul #cnn #bet #FoxNews #latimes #Crainschicago #usatoday #barronsonline #IBDinvestors #yahoofinance #espn #WGN #Apple #Tsla #IR
https://cutt.ly/5rnlBRbd
1 yr. ago
$GPOX News GPOPlus+ Activates Field Teams in Las Vegas as Initial Phase of National Rollout Strategy
https://cutt.ly/HrcF8Wm7
#B2B #NDAQ #NASDAQ #AI #wsj #nytimes #business #reuters #forbes #jakepaul #cnn #bet #FoxNews #latimes #Crainschicago #usatoday #barronsonline
https://cutt.ly/HrcF8Wm7
https://cutt.ly/HrcF8Wm7
#B2B #NDAQ #NASDAQ #AI #wsj #nytimes #business #reuters #forbes #jakepaul #cnn #bet #FoxNews #latimes #Crainschicago #usatoday #barronsonline
https://cutt.ly/HrcF8Wm7
